Inflammatory pathway genes associated with inter-individual variability in the trajectories of morning and evening fatigue in patients receiving chemotherapy

Cytokine

Volumn 91, Issue , 2017, Pages 187-210

  Wright, Fay ^a   Hammer, Marilyn ^b   Paul, Steven M ^c   Aouizerat, Bradley E ^d   Kober, Kord M ^c   Conley, Yvette P ^e   Cooper, Bruce A ^c   Dunn, Laura B ^f   Levine, Jon D ^g   DEramo Melkus, Gail ^h   Miaskowski, Christine ^c  

^a YALE UNIVERSITY SCHOOL OF NURSING   (United States)

^b MOUNT SINAI HOSPITAL   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d NEW YORK UNIVERSITY COLLEGE OF DENTISTRY   (United States)

^e UNIVERSITY OF PITTSBURGH   (United States)

^f STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g UNIVERSITY OF CALIFORNIA   (United States)

^h NEW YORK UNIVERSITY   (United States)

Author keywords

Cancer; Chemotherapy; Diurnal variability; Fatigue; Genes; Hierarchical linear modeling; Inflammation

Indexed keywords

ANTINEOPLASTIC AGENT; CHEMOKINE; CYTOKINE; I KAPPA B KINASE BETA; INFLAMMASOME; JANUS KINASE; MITOGEN ACTIVATED PROTEIN KINASE; STAT PROTEIN; STRESS ACTIVATED PROTEIN KINASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN;

ADULT; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER PATIENT; CHEMOKINE GENE; CONTROLLED STUDY; CYTOKINE GENE; DIGESTIVE SYSTEM CANCER; DISEASE SEVERITY; ETHNICITY; EVENING FATIGUE; FATIGUE; FEMALE; FEMALE GENITAL TRACT CANCER; GENE; GENETIC ASSOCIATION; GENETIC SCREENING; GENETIC VARIABILITY; HUMAN; ILLNESS TRAJECTORY; INFLAMMASOME GENE; INFLAMMATION; INFLAMMATORY PATHWAY GENE; JAK GENE; JNK GENE; LEE FATIGUE SCALE; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; MAP GENE; MAPK GENE; MORNING FATIGUE; MULTIPLE CYCLE TREATMENT; NF KAPPA B GENE; PROTEIN FUNCTION; QUALITY CONTROL; RACE; RATING SCALE; SELF REPORT; SINGLE NUCLEOTIDE POLYMORPHISM; STAT GENE; CHEMICALLY INDUCED; CLINICAL TRIAL; GENETICS; MULTICENTER STUDY; NEOPLASM;

CYTOKINES; FATIGUE; FEMALE; HUMANS; INFLAMMASOMES; JANUS KINASES; MALE; NEOPLASMS; NF-KAPPA B; POLYMORPHISM, SINGLE NUCLEOTIDE; STAT TRANSCRIPTION FACTORS;

EID: 85010042381     PISSN: 10434666     EISSN: 10960023     Source Type: Journal    
DOI: 10.1016/j.cyto.2016.12.023     Document Type: Article

References (141)

1. [1] Berger, A.M., Mitchell, S.A., Jacobsen, P.B., Pirl, W.F., Screening, evaluation, and management of cancer-related fatigue: Ready for implementation to practice?. CA Cancer J. Clin. 65:3 (2015), 190–211.
2. [2] Fisch, M.J., Zhao, F., O'Mara, A.M., Wang, X.S., Cella, D., Cleeland, C.S., Predictors of significant worsening of patient-reported fatigue over a 1-month timeframe in ambulatory patients with common solid tumors. Cancer 120:3 (2014), 442–450.
3. [3] Huang, H.P., Chen, M.L., Liang, J., Miaskowski, C., Changes in and predictors of severity of fatigue in women with breast cancer: A longitudinal study. Int. J. Nurs. Stud. 51:4 (2014), 582–592.
4. [4] Ancoli-Israel, S., Liu, L., Rissling, M., Natarajan, L., Neikrug, A.B., Palmer, B.W., Mills, P.J., Parker, B.A., Sadler, G.R., Maglione, J., Sleep, fatigue, depression, and circadian activity rhythms in women with breast cancer before and after treatment: a 1-year longitudinal study. Support. Care Cancer 22:9 (2014), 2535–2545.
5. [5] Trudel-Fitzgerald, C., Savard, J., Ivers, H., Evolution of cancer-related symptoms over an 18-month period. J. Pain Symptom Manage. 45:6 (2013), 1007–1018.
6. [6] Torres, M.A., Pace, T.W., Liu, T., Felger, J.C., Mister, D., Doho, G.H., Kohn, J.N., Barsevick, A.M., Long, Q., Miller, A.H., Predictors of depression in breast cancer patients treated with radiation: role of prior chemotherapy and nuclear factor kappa B. Cancer 119:11 (2013), 1951–1959.
7. [7] Miaskowski, C., Paul, S.M., Cooper, B.A., Lee, K., Dodd, M., West, C., Aouizerat, B.E., Swift, P.S., Wara, W., Trajectories of fatigue in men with prostate cancer before, during, and after radiation therapy. J. Pain Symptom Manage. 35:6 (2008), 632–643.
8. [8] Dhruva, A., Aouizerat, B.E., Cooper, B., Paul, S.M., Dodd, M., West, C., Wara, W., Lee, K., Dunn, L.B., Langford, D.J., Merriman, J.D., Baggott, C., Cataldo, J., Ritchie, C., Kober, K., Leutwyler, H., Miaskowski, C., Differences in morning and evening fatigue in oncology patients and their family caregivers. Eur. J. Oncol. Nurs. 17:6 (2013), 841–848.
9. [9] Wright, F., D'Eramo Melkus, G., Hammer, M., Schmidt, B.L., Knobf, M.T., Paul, S.M., Cartwright, F., Mastick, J., Cooper, B.A., Chen, L.M., Melisko, M., Levine, J.D., Kober, K., Aouizerat, B.E., Miaskowski, C., Predictors and trajectories of morning fatigue are distinct from evening fatigue. J. Pain Symptom Manage. 50:2 (2015), 176–189.
10. [10] Wright, F., D'Eramo Melkus, G., Hammer, M., Schmidt, B.L., Knobf, M.T., Paul, S.M., Cartwright, F., Mastick, J., Cooper, B.A., Chen, L.M., Melisko, M., Levine, J.D., Kober, K., Aouizerat, B.E., Miaskowski, C., Trajectories of evening fatigue in oncology outpatients receiving chemotherapy. J. Pain Symptom Manage. 50:2 (2015), 163–175.
11. [11] Kober, K.M., Cooper, B.A., Paul, S.M., Dunn, L.B., Levine, J.D., Wright, F., Hammer, M.J., Mastick, J., Venook, A., Aouizerat, B.E., Miaskowski, C., Subgroups of chemotherapy patients with distinct morning and evening fatigue trajectories. Support. Care Cancer 24:4 (2016), 1473–1485.
12. [12] Ratcliff, C.G., Lam, C.Y., Arun, B., Valero, V., Cohen, L., Ecological momentary assessment of sleep, symptoms, and mood during chemotherapy for breast cancer. Psychooncology 23:11 (2014), 1220–1228.
13. [13] Aouizerat, B.E., Dodd, M., Lee, K., West, C., Paul, S.M., Cooper, B.A., Wara, W., Swift, P., Dunn, L.B., Miaskowski, C., Preliminary evidence of a genetic association between tumor necrosis factor alpha and the severity of sleep disturbance and morning fatigue. Biol. Res. Nurs. 11:1 (2009), 27–41.
14. [14] Dhruva, A., Aouizerat, B.E., Cooper, B., Paul, S.M., Dodd, M., West, C., Wara, W., Lee, K., Dunn, L.B., Langford, D.J., Merriman, J.D., Baggott, C., Cataldo, J., Ritchie, C., Kober, K.M., Leutwyler, H., Miaskowski, C., Cytokine gene associations with self-report ratings of morning and evening fatigue in oncology patients and their family caregivers. Biol. Res. Nurs. 17:2 (2015), 175–184.
15. [15] Miaskowski, C., Dodd, M., Lee, K., West, C., Paul, S.M., Cooper, B.A., Wara, W., Swift, P.S., Dunn, L.B., Aouizerat, B.E., Preliminary evidence of an association between a functional interleukin-6 polymorphism and fatigue and sleep disturbance in oncology patients and their family caregivers. J. Pain Symptom Manage. 40:4 (2010), 531–544.
16. [16] LaVoy, E.C., Fagundes, C.P., Dantzer, R., Exercise, inflammation, and fatigue in cancer survivors. Exerc. Immunol. Rev. 22 (2016), 82–93.
17. [17] Dantzer, R., Heijnen, C.J., Kavelaars, A., Laye, S., Capuron, L., The neuroimmune basis of fatigue. Trends Neurosci. 37:1 (2014), 39–46.
18. [18] Saligan, L.N., Olson, K., Filler, K., Larkin, D., Cramp, F., Yennurajalingam, S., Escalante, C.P., del Giglio, A., Kober, K.M., Kamath, J., Palesh, O., Mustian, K., Multinational, G., Association of supportive care in cancer fatigue study group-biomarker working, the biology of cancer-related fatigue: a review of the literature. Support Care Cancer 23:8 (2015), 2461–2478.
19. [19] Vichaya, E.G., Chiu, G.S., Krukowski, K., Lacourt, T.E., Kavelaars, A., Dantzer, R., Heijnen, C.J., Walker, A.K., Mechanisms of chemotherapy-induced behavioral toxicities. Front. Neurosci., 9, 2015, 131.
20. [20] Pertl, M.M., Hevey, D., Boyle, N.T., Hughes, M.M., Collier, S., O'Dwyer, A.M., Harkin, A., Kennedy, M.J., Connor, T.J., C-reactive protein predicts fatigue independently of depression in breast cancer patients prior to chemotherapy. Brain Behav. Immun. 34 (2013), 108–119.
21. [21] Sha, F., Zhuang, S., Zhou, L., Zhang, L., Yang, Y., Zhang, S., Jiang, Y., Qiu, G., Chen, C., Zheng, J., Zhang, S., Biomarkers for cancer-related fatigue and adverse reactions to chemotherapy in lung cancer patients. Mol. Clin. Oncol. 3:1 (2015), 163–166.
22. [22] Ahlberg, K., Ekman, T., Gaston-Johansson, F., Levels of fatigue compared to levels of cytokines and hemoglobin during pelvic radiotherapy: a pilot study. Biol. Res. Nurs. 5:3 (2004), 203–210.
23. [23] Clevenger, L., Schrepf, A., Christensen, D., DeGeest, K., Bender, D., Ahmed, A., Goodheart, M.J., Penedo, F., Lubaroff, D.M., Sood, A.K., Lutgendorf, S.K., Sleep disturbance, cytokines, and fatigue in women with ovarian cancer. Brain Behav. Immun. 26:7 (2012), 1037–1044.
24. [24] de Raaf, P.J., Sleijfer, S., Lamers, C.H., Jager, A., Gratama, J.W., van der Rijt, C.C., Inflammation and fatigue dimensions in advanced cancer patients and cancer survivors: an explorative study. Cancer 118:23 (2012), 6005–6011.
25. [25] De Sanctis, V., Agolli, L., Visco, V., Monaco, F., Muni, R., Spagnoli, A., Campanella, B., Valeriani, M., Minniti, G., Osti, M.F., Amanti, C., Pellegrini, P., Brunetti, S., Costantini, A., Alfo, M., Torrisi, M.R., Marchetti, P., Enrici, R.M., Cytokines, fatigue, and cutaneous erythema in early stage breast cancer patients receiving adjuvant radiation therapy. BioMed. Res. Int., 2014, 2014, 523568.
26. [26] Inagaki, M., Isono, M., Okuyama, T., Sugawara, Y., Akechi, T., Akizuki, N., Fujimori, M., Mizuno, M., Shima, Y., Kinoshita, H., Uchitomi, Y., Plasma interleukin-6 and fatigue in terminally ill cancer patients. J. Pain Symptom Manage. 35:2 (2008), 153–161.
27. [27] Liu, L., Mills, P.J., Rissling, M., Fiorentino, L., Natarajan, L., Dimsdale, J.E., Sadler, G.R., Parker, B.A., Ancoli-Israel, S., Fatigue and sleep quality are associated with changes in inflammatory markers in breast cancer patients undergoing chemotherapy. Brain Behav. Immun. 26:5 (2012), 706–713.
28. [28] Schrepf, A., Clevenger, L., Christensen, D., DeGeest, K., Bender, D., Ahmed, A., Goodheart, M.J., Dahmoush, L., Penedo, F., Lucci, J.A. 3rd, Ganjei-Azar, P., Mendez, L., Markon, K., Lubaroff, D.M., Thaker, P.H., Slavich, G.M., Sood, A.K., Lutgendorf, S.K., Cortisol and inflammatory processes in ovarian cancer patients following primary treatment: relationships with depression, fatigue, and disability. Brain Behav. Immun. 30:Suppl (2013), S126–S134.
29. [29] Schubert, C., Hong, S., Natarajan, L., Mills, P.J., Dimsdale, J.E., The association between fatigue and inflammatory marker levels in cancer patients: a quantitative review. Brain Behav. Immun. 21:4 (2007), 413–427.
30. [30] Kwak, S.M., Choi, Y.S., Yoon, H.M., Kim, D.G., Song, S.H., Lee, Y.J., Yeom, C.H., Koh, S.J., Park, J., Lee, M.A., Suh, S.Y., The relationship between interleukin-6, tumor necrosis factor-alpha, and fatigue in terminally ill cancer patients. Palliat. Med. 26:3 (2012), 275–282.
31. [31] Rich, T., Innominato, P.F., Boerner, J., Mormont, M.C., Iacobelli, S., Baron, B., Jasmin, C., Levi, F., Elevated serum cytokines correlated with altered behavior, serum cortisol rhythm, and dampened 24-hour rest-activity patterns in patients with metastatic colorectal cancer. Clin. Cancer Res. 11:5 (2005), 1757–1764.
32. [32] Shafqat, A., Einhorn, L.H., Hanna, N., Sledge, G.W., Hanna, A., Juliar, B.E., Monahan, P., Bhatia, S., Screening studies for fatigue and laboratory correlates in cancer patients undergoing treatment. Ann. Oncol. 16:9 (2005), 1545–1550.
33. [33] Von Ah, D.M., Kang, D.H., Carpenter, J.S., Predictors of cancer-related fatigue in women with breast cancer before, during, and after adjuvant therapy. Cancer Nurs. 31:2 (2008), 134–144.
34. [34] Bower, J.E., Ganz, P.A., Irwin, M.R., Arevalo, J.M., Cole, S.W., Fatigue and gene expression in human leukocytes: increased NF-kappaB and decreased glucocorticoid signaling in breast cancer survivors with persistent fatigue. Brain Behav. Immun. 25:1 (2011), 147–150.
35. [35] Bower, J.E., Ganz, P.A., Tao, M.L., Hu, W., Belin, T.R., Sepah, S., Cole, S., Aziz, N., Inflammatory biomarkers and fatigue during radiation therapy for breast and prostate cancer. Clin. Cancer Res. 15:17 (2009), 5534–5540.
36. [36] Cameron, B.A., Bennett, B., Li, H., Boyle, F., DeSouza, P., Wilcken, N., Friedlander, M., Goldstein, D., Lloyd, A.R., Post-cancer fatigue is not associated with immune activation or altered cytokine production. Ann. Oncol. 23:11 (2012), 2890–2895.
37. [37] Collado-Hidalgo, A., Bower, J.E., Ganz, P.A., Irwin, M.R., Cole, S.W., Cytokine gene polymorphisms and fatigue in breast cancer survivors: early findings. Brain Behav. Immun. 22:8 (2008), 1197–1200.
38. [38] Dirksen, S.R., Kirschner, K.F., Belyea, M.J., Association of symptoms and cytokines in prostate cancer patients receiving radiation treatment. Biol. Res. Nurs. 16:3 (2014), 250–257.
39. [39] Gilbertson-White, S., Aouizerat, B.E., Miaskowski, C., Methodologic issues in the measurement of cytokines to elucidate the biological basis for cancer symptoms. Biol. Res. Nurs. 13:1 (2011), 15–24.
40. [40] Bower, J.E., Cancer-related fatigue–mechanisms, risk factors, and treatments. Nat. Rev. Clin. Oncol. 11:10 (2014), 597–609.
41. [41] Bower, J.E., Ganz, P.A., Aziz, N., Fahey, J.L., Fatigue and proinflammatory cytokine activity in breast cancer survivors. Psychosom. Med. 64:4 (2002), 604–611.
42. [42] Orre, I.J., Murison, R., Dahl, A.A., Ueland, T., Aukrust, P., Fossa, S.D., Levels of circulating interleukin-1 receptor antagonist and C-reactive protein in long-term survivors of testicular cancer with chronic cancer-related fatigue. Brain Behav. Immun. 23:6 (2009), 868–874.
43. [43] Bower, J.E., Ganz, P.A., Irwin, M.R., Kwan, L., Breen, E.C., Cole, S.W., Inflammation and behavioral symptoms after breast cancer treatment: do fatigue, depression, and sleep disturbance share a common underlying mechanism?. J. Clin. Oncol. 29:26 (2011), 3517–3522.
44. [44] Smith, A.K., Conneely, K.N., Pace, T.W., Mister, D., Felger, J.C., Kilaru, V., Akel, M.J., Vertino, P.M., Miller, A.H., Torres, M.A., Epigenetic changes associated with inflammation in breast cancer patients treated with chemotherapy. Brain Behav. Immun. 38 (2014), 227–236.
45. [45] Wang, X.S., Williams, L.A., Krishnan, S., Liao, Z., Liu, P., Mao, L., Shi, Q., Mobley, G.M., Woodruff, J.F., Cleeland, C.S., Serum sTNF-R1, IL-6, and the development of fatigue in patients with gastrointestinal cancer undergoing chemoradiation therapy. Brain Behav. Immun. 26:5 (2012), 699–705.
46. [46] Courtier, N., Gambling, T., Enright, S., Barrett-Lee, P., Abraham, J., Mason, M.D., Psychological and immunological characteristics of fatigued women undergoing radiotherapy for early-stage breast cancer. Support. Care Cancer 21:1 (2013), 173–181.
47. [47] Reinertsen, K.V., Grenaker Alnaes, G.I., Landmark-Hoyvik, H., Loge, J.H., Wist, E., Kristensen, V.N., Fossa, S.D., Edvardsen, H., Fatigued breast cancer survivors and gene polymorphisms in the inflammatory pathway. Brain Behav. Immun. 25:7 (2011), 1376–1383.
48. [48] Hsiao, C.P., Araneta, M., Wang, X.M., Saligan, L.N., The association of IFI27 expression and fatigue intensification during localized radiation therapy: implication of a para-inflammatory bystander response. Int. J. Mol. Sci. 14:8 (2013), 16943–16957.
49. [49] Hsiao, C.P., Wang, D., Kaushal, A., Saligan, L., Mitochondria-related gene expression changes are associated with fatigue in patients with nonmetastatic prostate cancer receiving external beam radiation therapy. Cancer Nurs. 36:3 (2013), 189–197.
50. [50] Landmark-Hoyvik, H., Reinertsen, K.V., Loge, J.H., Fossa, S.D., Borresen-Dale, A.L., Dumeaux, V., Alterations of gene expression in blood cells associated with chronic fatigue in breast cancer survivors. Pharmacogenom. J. 9:5 (2009), 333–340.
51. [51] Light, K.C., Agarwal, N., Iacob, E., White, A.T., Kinney, A.Y., VanHaitsma, T.A., Aizad, H., Hughen, R.W., Bateman, L., Light, A.R., Differing leukocyte gene expression profiles associated with fatigue in patients with prostate cancer versus chronic fatigue syndrome. Psychoneuroendocrinology 38:12 (2013), 2983–2995.
52. [52] Saligan, L.N., Hsiao, C.P., Wang, D., Wang, X.M., St John, L., Kaushal, A., Citrin, D., Barb, J.J., Munson, P.J., Dionne, R.A., Upregulation of alpha-synuclein during localized radiation therapy signals the association of cancer-related fatigue with the activation of inflammatory and neuroprotective pathways. Brain Behav. Immun. 27:1 (2013), 63–70.
53. [53] Kober, K.M., Dunn, L., Mastick, J., Cooper, B., Langford, D., Melisko, M., Venook, A., Chen, L.M., Wright, F., Hammer, M., Schmidt, B.L., Levine, J., Miaskowski, C., Aouizerat, B.E., Gene expression profiling of evening fatigue in women undergoing chemotherapy for breast cancer. Biol. Res. Nurs. 18:4 (2016), 370–385.
54. [54] Bower, J.E., Ganz, P.A., Irwin, M.R., Castellon, S., Arevalo, J., Cole, S.W., Cytokine genetic variations and fatigue among patients with breast cancer. J. Clin. Oncol. 31:13 (2013), 1656–1661.
55. [55] Jim, H.S., Park, J.Y., Permuth-Wey, J., Rincon, M.A., Phillips, K.M., Small, B.J., Jacobsen, P.B., Genetic predictors of fatigue in prostate cancer patients treated with androgen deprivation therapy: preliminary findings. Brain Behav. Immun. 26:7 (2012), 1030–1036.
56. [56] Bower, J.E., Lamkin, D.M., Inflammation and cancer-related fatigue: mechanisms, contributing factors, and treatment implications. Brain Behav. Immun. 30:Suppl (2013), S48–S57.
57. [57] Shi, Q., Wang, X.S., Li, G., Shah, N.D., Orlowski, R.Z., Williams, L.A., Mendoza, T.R., Cleeland, C.S., Racial/ethnic disparities in inflammatory gene single-nucleotide polymorphisms as predictors of a high risk for symptom burden in patients with multiple myeloma 1 year after diagnosis. Cancer 121:7 (2015), 1138–1146.
58. [58] Rausch, S.M., Clark, M.M., Patten, C., Liu, H., Felten, S., Li, Y., Sloan, J., Yang, P., Relationship between cytokine gene single nucleotide polymorphisms and symptom burden and quality of life in lung cancer survivors. Cancer 116:17 (2010), 4103–4113.
59. [59] Wood, L.J., Weymann, K., Inflammation and neural signaling: etiologic mechanisms of the cancer treatment-related symptom cluster. Curr. Opin. Support Palliat Care 7:1 (2013), 54–59.
60. [60] Zhang, Z.T., Du, X.M., Ma, X.J., Zong, Y., Chen, J.K., Yu, C.L., Liu, Y.G., Chen, Y.C., Zhao, L.J., Lu, G.C., Activation of the NLRP3 inflammasome in lipopolysaccharide-induced mouse fatigue and its relevance to chronic fatigue syndrome. J. Neuroinflamm., 13(1), 2016, 71.
61. [61] Ramanan, V.K., Shen, L., Moore, J.H., Saykin, A.J., Pathway analysis of genomic data: concepts, methods, and prospects for future development. Trends Genet. 28:7 (2012), 323–332.
62. [62] Miaskowski, C., Cooper, B.A., Melisko, M., Chen, L.M., Mastick, J., West, C., Paul, S.M., Dunn, L.B., Schmidt, B.L., Hammer, M., Cartwright, F., Wright, F., Langford, D.J., Lee, K., Aouizerat, B.E., Disease and treatment characteristics do not predict symptom occurrence profiles in oncology outpatients receiving chemotherapy. Cancer 120:15 (2014), 2371–2378.
63. [63] Alfaro, E., Dhruva, A., Langford, D.J., Koetters, T., Merriman, J.D., West, C., Dunn, L.B., Paul, S.M., Cooper, B., Cataldo, J., Hamolsky, D., Elboim, C., Kober, K., Aouizerat, B.E., Miaskowski, C., Associations between cytokine gene variations and self-reported sleep disturbance in women following breast cancer surgery. Eur. J. Oncol. Nurs. 18:1 (2014), 85–93.
64. [64] Aouizerat, B.E., Dhruva, A., Paul, S.M., Cooper, B.A., Kober, K.M., Miaskowski, C., Phenotypic and molecular evidence suggests that decrements in morning and evening energy are distinct but related symptoms. J. Pain Symptom Manage. 50:5 (2015), 599–614 e3.
65. [65] Karnofsky, D., Performance Scale. 1977, Plenum Press, New York, NY.
66. [66] Sangha, O., Stucki, G., Liang, M.H., Fossel, A.H., Katz, J.N., The Self-Administered Comorbidity Questionnaire: a new method to assess comorbidity for clinical and health services research. Arthritis Rheum. 49:2 (2003), 156–163.
67. [67] Spielberger, C.G., Gorsuch, R.L., Suchene, R., Vagg, P.R., Jacobs, G.A., Manual for the State-Anxiety (Form Y): Self Evaluation Questionnaire. 1983, Consulting Psychologists Press, Palo Alto, CA.
68. [68] Radloff, L.S., The CES-D Scale: A self-report depression scale for research in the general population. Appl. Psychol. Meas. 1:3 (1977), 385–401.
69. [69] Lee, K.A., Self-reported sleep disturbances in employed women. Sleep 15:6 (1992), 493–498.
70. [70] Lee, K.A., Hicks, G., Nino-Murcia, G., Validity and reliability of a scale to assess fatigue. Psychiatry Res. 36:3 (1991), 291–298.
71. [71] IBM SPSS Statistics for Windows, Version 22, IBM Corp, Armonk, NY, Released 2013.
72. [72] Halder, I., Shriver, M., Thomas, M., Fernandez, J.R., Frudakis, T., A panel of ancestry informative markers for estimating individual biogeographical ancestry and admixture from four continents: utility and applications. Hum. Mutat. 29:5 (2008), 648–658.
73. [73] Hoggart, C.J., Parra, E.J., Shriver, M.D., Bonilla, C., Kittles, R.A., Clayton, D.G., McKeigue, P.M., Control of confounding of genetic associations in stratified populations. Am. J. Hum. Genet. 72:6 (2003), 1492–1504.
74. [74] Tian, C., Gregersen, P.K., Seldin, M.F., Accounting for ancestry: population substructure and genome-wide association studies. Hum. Mol. Genet. 17:R2 (2008), R143–R150.
75. [75] Price, A.L., Patterson, N.J., Plenge, R.M., Weinblatt, M.E., Shadick, N.A., Reich, D., Principal components analysis corrects for stratification in genome-wide association studies. Nat. Genet. 38:8 (2006), 904–909.
76. [76] Raudenbush, S.W., Bryk, A., Hierarchical Linear Models: Applications and Data Analysis Methods. second ed., 2002, Sage Publications, Thousand Oaks, CA.
77. [77] McCann, B., Miaskowski, C., Koetters, T., Baggott, C., West, C., Levine, J.D., Elboim, C., Abrams, G., Hamolsky, D., Dunn, L., Rugo, H., Dodd, M., Paul, S.M., Neuhaus, J., Cooper, B., Schmidt, B., Langford, D., Cataldo, J., Aouizerat, B.E., Associations between pro- and anti-inflammatory cytokine genes and breast pain in women prior to breast cancer surgery. J. Pain 13:5 (2012), 425–437.
78. [78] Miaskowski, C., Cooper, B.A., Dhruva, A., Dunn, L.B., Langford, D.J., Cataldo, J.K., Baggott, C.R., Merriman, J.D., Dodd, M., Lee, K., West, C., Paul, S.M., Aouizerat, B.E., Evidence of associations between cytokine genes and subjective reports of sleep disturbance in oncology patients and their family caregivers. PLoS ONE, 7(7), 2012, e40560.
79. [79] Miaskowski, C., Cataldo, J.K., Baggott, C.R., West, C., Dunn, L.B., Dhruva, A., Merriman, J.D., Langford, D.J., Kober, K.M., Paul, S.M., Cooper, B.A., Aouizerat, B.E., Cytokine gene variations associated with trait and state anxiety in oncology patients and their family caregivers. Support. Care Cancer 23:4 (2015), 953–965.
80. [80] Merriman, J.D., Aouizerat, B.E., Cataldo, J.K., Dunn, L., Cooper, B.A., West, C., Paul, S.M., Baggott, C.R., Dhruva, A., Kober, K., Langford, D.J., Leutwyler, H., Ritchie, C.S., Abrams, G., Dodd, M., Elboim, C., Hamolsky, D., Melisko, M., Miaskowski, C., Association between an interleukin 1 receptor, type I promoter polymorphism and self-reported attentional function in women with breast cancer. Cytokine 65:2 (2014), 192–201.
81. [81] Rothman, K.J., No adjustments are needed for multiple comparisons. Epidemiology 1:1 (1990), 43–46.
82. [82] Hattersley, A.T., McCarthy, M.I., What makes a good genetic association study?. Lancet 366:9493 (2005), 1315–1323.
83. [83] Kumar, P., Henikoff, S., Ng, P.C., Predicting the effects of coding non-synonymous variants on protein function using the SIFT algorithm. Nat. Protoc. 4:7 (2009), 1073–1081.
84. [84] Adzhubei, I.A., Schmidt, S., Peshkin, L., Ramensky, V.E., Gerasimova, A., Bork, P., Kondrashov, A.S., Sunyaev, S.R., A method and server for predicting damaging missense mutations. Nat. Methods 7:4 (2010), 248–249.
85. [85] Barsevick, A., Frost, M., Zwinderman, A., Hall, P., Halyard, M., Consortium, G., I'm so tired: biological and genetic mechanisms of cancer-related fatigue. Qual. Life Res. 19:10 (2010), 1419–1427.
86. [86] Berger, A.M., Abernethy, A.P., Atkinson, A., Barsevick, A.M., Breitbart, W.S., Cella, D., Cimprich, B., Cleeland, C., Eisenberger, M.A., Escalante, C.P., Jacobsen, P.B., Kaldor, P., Ligibel, J.A., Murphy, B.A., O'Connor, T., Pirl, W.F., Rodler, E., Rugo, H.S., Thomas, J., Wagner, L.I., NCCN clinical practice guidelines cancer-related fatigue. J. Natl. Compr. Canc. Netw. 8:8 (2010), 904–931.
87. [87] Bower, J.E., Fatigue, brain, behavior, and immunity: summary of the 2012 Named Series on fatigue. Brain Behav. Immun. 26:8 (2012), 1220–1223.
88. [88] Cleeland, C.S., Bennett, G.J., Dantzer, R., Dougherty, P.M., Dunn, A.J., Meyers, C.A., Miller, A.H., Payne, R., Reuben, J.M., Wang, X.S., Lee, B.N., Are the symptoms of cancer and cancer treatment due to a shared biologic mechanism? A cytokine-immunologic model of cancer symptoms. Cancer 97:11 (2003), 2919–2925.
89. [89] Lee, B.N., Dantzer, R., Langley, K.E., Bennett, G.J., Dougherty, P.M., Dunn, A.J., Meyers, C.A., Miller, A.H., Payne, R., Reuben, J.M., Wang, X.S., Cleeland, C.S., A cytokine-based neuroimmunologic mechanism of cancer-related symptoms. NeuroImmunoModulation 11:5 (2004), 279–292.
90. [90] Seruga, B., Zhang, H., Bernstein, L.J., Tannock, I.F., Cytokines and their relationship to the symptoms and outcome of cancer. Nat. Rev. Cancer 8:11 (2008), 887–899.
91. [91] Saligan, L.N., Kim, H.S., A systematic review of the association between immunogenomic markers and cancer-related fatigue. Brain Behav. Immun. 26:6 (2012), 830–848.
92. [92] Ruddle, N.H., Lymphotoxin and TNF: how it all began-a tribute to the travelers. Cytokine Growth Factor Rev. 25:2 (2014), 83–89.
93. [93] Upadhyay, V., Fu, Y.X., Lymphotoxin signalling in immune homeostasis and the control of microorganisms. Nat. Rev. Immunol. 13:4 (2013), 270–279.
94. [94] Upadhyay, V., Fu, Y.X., Lymphotoxin organizes contributions to host defense and metabolic illness from innate lymphoid cells. Cytokine Growth Factor Rev. 25:2 (2014), 227–233.
95. [95] Boraska, V., Rayner, N.W., Groves, C.J., Frayling, T.M., Diakite, M., Rockett, K.A., Kwiatkowski, D.P., Day-Williams, A.G., McCarthy, M.I., Zeggini, E., Large-scale association analysis of TNF/LTA gene region polymorphisms in type 2 diabetes. BMC Med. Genet., 11, 2010, 69.
96. [96] Ikeda, S., Tanaka, N., Arai, T., Chida, K., Muramatsu, M., Sawabe, M., Polymorphisms of LTA, LGALS2, and PSMA6 genes and coronary atherosclerosis: a pathological study of 1503 consecutive autopsy cases. Atherosclerosis 221:2 (2012), 458–460.
97. [97] Kallio, K.A., Marchesani, M., Vlachopoulou, E., Mantyla, P., Paju, S., Buhlin, K., Suominen, A.L., Contreras, J., Knuuttila, M., Hernandez, M., Huumonen, S., Nieminen, M.S., Perola, M., Sinisalo, J., Lokki, M.L., Pussinen, P.J., Genetic variation on the BAT1-NFKBIL1-LTA region of major histocompatibility complex class III associates with periodontitis. Infect. Immun. 82:5 (2014), 1939–1948.
98. [98] Upadhyay, V., Fu, Y.X., Linking the microbiota and metabolic disease with lymphotoxin. Int. Immunol. 25:7 (2013), 397–403.
99. [99] Lee, K.A., Gay, C., Pullinger, C.R., Hennessy, M.D., Zak, R.S., Aouizerat, B.E., Cytokine polymorphisms are associated with poor sleep maintenance in adults living with human immunodeficiency virus/acquired immunodeficiency syndrome. Sleep 37:3 (2014), 453–463.
100. [100] Lee, K.A., Gay, C.L., Lerdal, A., Pullinger, C.R., Aouizerat, B.E., Cytokine polymorphisms are associated with fatigue in adults living with HIV/AIDS. Brain Behav. Immun. 40 (2014), 95–103.
101. [101] Bower, J.E., Greendale, G., Crosswell, A.D., Garet, D., Sternlieb, B., Ganz, P.A., Irwin, M.R., Olmstead, R., Arevalo, J., Cole, S.W., Yoga reduces inflammatory signaling in fatigued breast cancer survivors: a randomized controlled trial. Psychoneuroendocrinology 43 (2014), 20–29.
102. [102] Zhang, X.J., Huang, W., Yang, S., Sun, L.D., Zhang, F.Y., Zhu, Q.X., Zhang, F.R., Zhang, C., Du, W.H., Pu, X.M., Li, H., Xiao, F.L., Wang, Z.X., Cui, Y., Hao, F., Zheng, J., Yang, X.Q., Cheng, H., He, C.D., Liu, X.M., Xu, L.M., Zheng, H.F., Zhang, S.M., Zhang, J.Z., Wang, H.Y., Cheng, Y.L., Ji, B.H., Fang, Q.Y., Li, Y.Z., Zhou, F.S., Han, J.W., Quan, C., Chen, B., Liu, J.L., Li, D., Fan, L., Zhang, A.P., Liu, S.X., Yang, C.J., Wang, P.G., Zhou, W.M., Lin, G.S., Wu, W.D., Fan, X., Gao, M., Yang, B.Q., Lu, W.S., Zhang, Z., Zhu, K.J., Shen, S.K., Li, M., Zhang, X.Y., Cao, T.T., Ren, W., Zhang, X., He, J., Tang, X.F., Lu, S., Yang, J.Q., Zhang, L., Wang, D.N., Yuan, F., Yin, X.Y., Huang, H.J., Wang, H.F., Lin, X.Y., Liu, J.J., Psoriasis genome-wide association study identifies susceptibility variants within LCE gene cluster at 1q21. Nat. Genet. 41:2 (2009), 205–210.
103. [103] Howard Tripp, N., Tarn, J., Natasari, A., Gillespie, C., Mitchell, S., Hackett, K.L., Bowman, S.J., Price, E., Pease, C.T., Emery, P., Lanyon, P., Hunter, J., Gupta, M., Bombardieri, M., Sutcliffe, N., Pitzalis, C., McLaren, J., Cooper, A., Regan, M., Giles, I., Isenberg, D.A., Saravanan, V., Coady, D., Dasgupta, B., McHugh, N., Young-Min, S., Moots, R., Gendi, N., Akil, M., Griffiths, B., Lendrem, D.W., Ng, W.F., Fatigue in primary Sjogren's syndrome is associated with lower levels of proinflammatory cytokines. RMD Open, 2(2), 2016, e000282.
104. [104] Dantzer, R., O'Connor, J.C., Freund, G.G., Johnson, R.W., Kelley, K.W., From inflammation to sickness and depression: when the immune system subjugates the brain. Nat. Rev. Neurosci. 9:1 (2008), 46–56.
105. [105] Jha, S., Pan-Yun Ting, J., Holding the inflammatory system in check: NLRs keep it cool. F1000 Prime Rep., 7, 2015, 15.
106. [106] Martinon, F., Mayor, A., Tschopp, J., The inflammasomes: guardians of the body. Annu. Rev. Immunol. 27:1 (2009), 229–265.
107. [107] Latz, E., Xiao, T.S., Stutz, A., Activation and regulation of the inflammasomes. Nat. Rev. Immunol. 13:6 (2013), 397–411.
108. [108] Borm, M.E., van Bodegraven, A.A., Mulder, C.J., Kraal, G., Bouma, G., The effect of NOD2 activation on TLR2-mediated cytokine responses is dependent on activation dose and NOD2 genotype. Genes Immun. 9:3 (2008), 274–278.
109. [109] Kutikhin, A.G., Role of NOD1/CARD4 and NOD2/CARD15 gene polymorphisms in cancer etiology. Hum. Immunol. 72:10 (2011), 955–968.
110. [110] Glas, J., Seiderer, J., Tillack, C., Pfennig, S., Beigel, F., Jurgens, M., Olszak, T., Laubender, R.P., Weidinger, M., Muller-Myhsok, B., Goke, B., Ochsenkuhn, T., Lohse, P., Diegelmann, J., Czamara, D., Brand, S., The NOD2 single nucleotide polymorphisms rs2066843 and rs2076756 are novel and common Crohn's disease susceptibility gene variants. PLoS ONE, 5(12), 2010, e14466.
111. [111] Yao, Q., Shen, M., McDonald, C., Lacbawan, F., Moran, R., Shen, B., NOD2-associated autoinflammatory disease: a large cohort study. Rheumatology 54:10 (2015), 1904–1912.
112. [112] Connelly, T.M., Berg, A.S., Harris, L. 3rd, Brinton, D., Deiling, S., Koltun, W.A., Genetic determinants associated with early age of diagnosis of IBD. Dis. Colon Rectum 58:3 (2015), 321–327.
113. [113] Anand, P.K., Kanneganti, T.D., NLRP6 in infection and inflammation. Microbes Infect. 15:10–11 (2013), 661–668.
114. [114] Ydens, E., Demon, D., Lornet, G., De Winter, V., Timmerman, V., Lamkanfi, M., Janssens, S., Nlrp6 promotes recovery after peripheral nerve injury independently of inflammasomes. J. Neuroinflamm., 12(1), 2015, 143.
115. [115] Sharma, D., Kanneganti, T.D., The cell biology of inflammasomes: Mechanisms of inflammasome activation and regulation. J. Cell Biol. 213:6 (2016), 617–629.
116. [116] Wang, A., Ling, Z., Yang, Z., Kiela, P.R., Wang, T., Wang, C., Cao, L., Geng, F., Shen, M., Ran, X., Su, Y., Cheng, T., Wang, J., Gut microbial dysbiosis may predict diarrhea and fatigue in patients undergoing pelvic cancer radiotherapy: a pilot study. PLoS ONE, 10(5), 2015, e0126312.
117. [117] Docherty, L.E., Rezwan, F.I., Poole, R.L., Turner, C.L., Kivuva, E., Maher, E.R., Smithson, S.F., Hamilton-Shield, J.P., Patalan, M., Gizewska, M., Peregud-Pogorzelski, J., Beygo, J., Buiting, K., Horsthemke, B., Soellner, L., Begemann, M., Eggermann, T., Baple, E., Mansour, S., Temple, I.K., Mackay, D.J., Mutations in NLRP5 are associated with reproductive wastage and multilocus imprinting disorders in humans. Nat. Commun., 6, 2015, 8086.
118. [118] Ebersole, J.L., Kirakodu, S., Novak, M.J., Exposto, C.R., Stromberg, A.J., Shen, S., Orraca, L., Gonzalez-Martinez, J., Gonzalez, O.A., Effects of aging in the expression of NOD-like receptors and inflammasome-related genes in oral mucosa. Mol. Oral. Microbiol. 31:1 (2016), 18–32.
119. [119] G. Poli, S. Brancorsini, G. Cochetti, F. Barillaro, M.G. Egidi, E. Mearini, Expression of inflammasome-related genes in bladder cancer and their association with cytokeratin 20 messenger RNA, Urol Oncol 33(12) (2015) 505 e1–7.
120. [120] Zhu, L., Hu, Z., Liu, J., Gao, J., Lin, B., Gene expression profile analysis identifies metastasis and chemoresistance-associated genes in epithelial ovarian carcinoma cells. Med. Oncol., 32(1), 2015, 426.
121. [121] Dufner, A., Duncan, G.S., Wakeham, A., Elford, A.R., Hall, H.T., Ohashi, P.S., Mak, T.W., CARD6 is interferon inducible but not involved in nucleotide-binding oligomerization domain protein signaling leading to NF-kappaB activation. Mol. Cell. Biol. 28:5 (2008), 1541–1552.
122. [122] Kim, S.S., Ahn, C.H., Kang, M.R., Kim, Y.R., Kim, H.S., Yoo, N.J., Lee, S.H., Expression of CARD6, an NF-kappaB activator, in gastric, colorectal and oesophageal cancers. Pathology 42:1 (2010), 50–53.
123. [123] Li, L., Chen, W., Zhu, Y., Wang, X., Jiang, D.S., Huang, F., Wang, L., Xiang, F., Qin, W., Wang, Q., Zhang, R., Zhu, X., Li, H., Chen, X., Caspase recruitment domain 6 protects against cardiac hypertrophy in response to pressure overload. Hypertension 64:1 (2014), 94–102.
124. [124] Iwata, M., Ota, K.T., Duman, R.S., The inflammasome: pathways linking psychological stress, depression, and systemic illnesses. Brain Behav. Immun. 31 (2013), 105–114.
125. [125] Roxburgh, C.S., McMillan, D.C., Therapeutics targeting innate immune/inflammatory responses through the interleukin-6/JAK/STAT signal transduction pathway in patients with cancer. Transl. Res. 167:1 (2016), 61–66.
126. [126] Futosi, K., Fodor, S., Mocsai, A., Neutrophil cell surface receptors and their intracellular signal transduction pathways. Int. Immunopharmacol. 17:3 (2013), 638–650.
127. [127] Sabio, G., Davis, R.J., TNF and MAP kinase signalling pathways. Semin. Immunol. 26:3 (2014), 237–245.
128. [128] He, Q., Gong, Y., Gower, L., Yang, X., Friesel, R.E., Sef regulates epithelial-mesenchymal transition in breast cancer cells. J. Cell. Biochem. 117:10 (2016), 2346–2356.
129. [129] Mellett, M., Atzei, P., Bergin, R., Horgan, A., Floss, T., Wurst, W., Callanan, J.J., Moynagh, P.N., Orphan receptor IL-17RD regulates Toll-like receptor signalling via SEFIR/TIR interactions. Nat. Commun., 6, 2015, 6669.
130. [130] Biswas, R., Angshuman, B., NFkB pathway and inhibition: an overview. Comput. Mol. Biol. 6:1 (2016), 1–20.
131. [131] Hoesel, B., Schmid, J.A., The complexity of NF-kappaB signaling in inflammation and cancer. Mol. Cancer, 12(1), 2013, 86.
132. [132] Lawrence, T., The nuclear factor NF-kappaB pathway in inflammation. Cold Spring Harb. Perspect. Biol., 1(6), 2009, a001651.
133. [133] Sakoda, Y., Nagai, T., Murata, S., Mizuno, Y., Kurosawa, H., Shoda, H., Morishige, N., Yanai, R., Sonoda, K.H., Tamada, K., Pathogenic function of herpesvirus entry mediator in experimental autoimmune uveitis by induction of Th1- and Th17-Type T cell responses. J. Immunol. 196:7 (2016), 2947–2954.
134. [134] Li, D., Fu, Z., Chen, S., Yuan, W., Liu, Y., Li, L., Pang, D., Li, D., HVEM gene polymorphisms are associated with sporadic breast cancer in Chinese women. PLoS ONE, 8(8), 2013, e71040.
135. [135] Chen, W., Tang, W.R., Zhang, M., Chang, K., Wei, Y.L., Association of DR4 (TRAIL-R1) polymorphisms with cancer risk in Caucasians: an updated meta-analysis. Asian Pac. J. Cancer Prev. 15:6 (2014), 2889–2892.
136. [136] Webb, E., Broderick, P., Lubbe, S., Chandler, I., Tomlinson, I., Houlston, R.S., A genome-wide scan of 10 000 gene-centric variants and colorectal cancer risk. Eur. J. Hum. Genet. 17:11 (2009), 1507–1514.
137. [137] Lee, W.H., Wu, H.H., Huang, C.K., Targeting interleukin-17 receptors. Oncotarget 6:21 (2015), 18244–18245.
138. [138] Huang, C.K., Yang, C.Y., Jeng, Y.M., Chen, C.L., Wu, H.H., Chang, Y.C., Ma, C., Kuo, W.H., Chang, K.J., Shew, J.Y., Lee, W.H., Autocrine/paracrine mechanism of interleukin-17B receptor promotes breast tumorigenesis through NF-kappaB-mediated antiapoptotic pathway. Oncogene 33:23 (2014), 2968–2977.
139. [139] Kim, Y.G., Ihm, C.G., Lee, T.W., Lee, S.H., Jeong, K.H., Moon, J.Y., Chung, J.H., Kim, S.K., Kim, Y.H., Association of genetic polymorphisms of interleukins with new-onset diabetes after transplantation in renal transplantation. Transplantation 93:9 (2012), 900–907.
140. [140] Xu, Y., Wang, D., Luo, Y., Li, W., Shan, Y., Tan, X., Zhu, C., Beta amyloid-induced upregulation of death receptor 6 accelerates the toxic effect of N-terminal fragment of amyloid precursor protein. Neurobiol. Aging 36:1 (2015), 157–168.
141. [141] Jang, S.W., Lim, S.G., Suk, K., Lee, W.H., Activation of lymphotoxin-beta receptor enhances the LPS-induced expression of IL-8 through NF-kappaB and IRF-1. Immunol. Lett. 165:2 (2015), 63–69.